17 results on '"Visser LE"'
Search Results
2. Overanticoagulation is associated with renal function decline.
- Author
-
van Blijderveen JC, Verhamme KM, Zietse R, Visser LE, Romio SA, Buhre PN, Sturkenboom MC, Hofman A, Straus SM, and Stricker BH
- Subjects
- Aged, Anticoagulants adverse effects, Cohort Studies, Drug Overdose, Female, Glomerular Filtration Rate drug effects, Humans, International Normalized Ratio, Male, Middle Aged, Prospective Studies, Warfarin adverse effects, Anticoagulants administration & dosage, Kidney drug effects, Kidney physiopathology, Vitamin K antagonists & inhibitors, Warfarin administration & dosage
- Abstract
Background: Recent studies suggest that overanticoagulation impairs renal function in patients on warfarin therapy, due to renal tubular obstruction from glomerular hemorrhage., Methods: Data from the Rotterdam Study (The Netherlands), a prospective population-based cohort study of patients 55 years and older, were used for this study. Information on vitamin K antagonist (VKA) therapy was obtained from the regional anticoagulation clinic, where prothrombin times were monitored every 1-6 weeks depending on target level and stability of the international normalized ratio (INR). Linear regression was performed to study the association between the cumulative number of instances of overanticoagulation (defined as a measurement of an INR >6.0) and the change in renal function between baseline and third examination round based on estimated glomerular filtration rate (CKD-EPI equation). Age, sex, baseline renal function, baseline and incident heart failure, and indication for VKA therapy were included as potential confounders., Results: Information was available for analysis on 2,802 study participants in whom overanticoagulation was significantly associated with a decline in renal function, after adjustment for confounding by age, sex, heart failure, baseline glomerular filtration rate and indication for VKA therapy (-0.180 ml/min per 1.73 m(2) per year per event for INR >6.0, p = 0.030)., Conclusions: Overanticoagulation (INR >6.0) is associated with a decline in renal function. Further studies are needed to evaluate the causal role of different degrees of overanticoagulation, including transient effects, in high-risk groups, and the association with the new oral anticoagulants.
- Published
- 2013
- Full Text
- View/download PDF
3. Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study.
- Author
-
van Schie RM, el Khedr N, Verhoef TI, Teichert M, Stricker BH, Hofman A, Buhre PN, Wessels JA, Schalekamp T, le Cessie S, van der Meer FJ, Rosendaal FR, de Boer A, Maitland-van der Zee AH, and Visser LE
- Subjects
- Aged, Aged, 80 and over, Algorithms, Cytochrome P-450 CYP2C9, Dose-Response Relationship, Drug, Female, Genotype, Humans, International Normalized Ratio, Male, Middle Aged, Pharmacogenetics, Phenprocoumon administration & dosage, Polymorphism, Single Nucleotide, Precision Medicine, Vitamin K Epoxide Reductases, Warfarin administration & dosage, Acenocoumarol administration & dosage, Acenocoumarol adverse effects, Anticoagulants administration & dosage, Aryl Hydrocarbon Hydroxylases genetics, Mixed Function Oxygenases genetics
- Abstract
Aim: To evaluate the performance of the European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) acenocoumarol dose algorithms in an independent data set. The EU-PACT trial investigates the added value of pretreatment genotyping for use of warfarin, phenprocoumon and acenocoumarol., Patients & Methods: External validation was performed in the Rotterdam Study cohort using information about 707 acenocoumarol users. R(2), which measures the strength of correlation between the predicted and observed acenocoumarol dose, mean absolute error and mean squared error were calculated to evaluate the performance of the original algorithm., Results: Validation resulted in a R(2) of 52.7 and 12.9% compared with an R(2) of 52.6 and 17.8% in the original study for the genotype-guided and nongenotype-guided dose algorithm, respectively. For the genotype-guided dose algorithm, the mean absolute error was 0.48 mg/day and the mean squared error was 0.38 (mg/day)(2). For the nongenotype-guided dose algorithm, the mean absolute error was 0.62 mg/day and the mean squared error was 0.63 (mg/day)(2)., Conclusion: The EU-PACT acenocoumarol algorithm performs just as accurately in this study as in the original study, which implies applicability in various populations.
- Published
- 2012
- Full Text
- View/download PDF
4. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.
- Author
-
Verhoef TI, Redekop WK, Buikema MM, Schalekamp T, Van Der Meer FJ, Le Cessie S, Wessels JA, Van Schie RM, De Boer A, Teichert M, Visser LE, and Maitland-Van Der Zee AH
- Subjects
- Acenocoumarol administration & dosage, Acenocoumarol adverse effects, Aged, Anticoagulants administration & dosage, Anticoagulants adverse effects, Aryl Hydrocarbon Hydroxylases metabolism, Cytochrome P-450 CYP2C9, Drug Administration Schedule, Drug Dosage Calculations, Drug Monitoring methods, Female, Gene Frequency, Genotype, Humans, International Normalized Ratio, Male, Medication Errors prevention & control, Mixed Function Oxygenases metabolism, Netherlands, Pharmacogenetics, Phenotype, Polymorphism, Genetic, Predictive Value of Tests, Risk Assessment, Risk Factors, Time Factors, Vitamin K Epoxide Reductases, Acenocoumarol pharmacokinetics, Anticoagulants pharmacokinetics, Aryl Hydrocarbon Hydroxylases genetics, Blood Coagulation drug effects, Mixed Function Oxygenases genetics
- Abstract
Background: The required acenocoumarol dose and the risk of underanticoagulation and overanticoagulation are associated with the CYP2C9 and VKORC1 genotypes. However, the duration of the effects of these genes on anticoagulation is not yet known., Objectives: In the present study, the effects of these polymorphisms on the risk of underanticoagulation and overanticoagulation over time after the start of acenocoumarol were investigated., Patients/methods: In three cohorts, we analyzed the relationship between the CYP2C9 and VKORC1 genotypes and the incidence of subtherapeutic or supratherapeutic International Normalized Ratio (INR) values (< 2 and > 3.5) or severe overanticoagulation (INR > 6) for different time periods after treatment initiation., Results: Patients with polymorphisms in CYP2C9 and VKORC1 had a higher risk of overanticoagulation (up to 74%) and a lower risk of underanticoagulation (down to 45%) in the first month of treatment with acenocoumarol, but this effect diminished after 1-6 months., Conclusions: Knowledge of the patient's genotype therefore might assist physicians to adjust doses in the first month(s) of therapy., (© 2012 International Society on Thrombosis and Haemostasis.)
- Published
- 2012
- Full Text
- View/download PDF
5. Selective serotonin re-uptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment.
- Author
-
Teichert M, Visser LE, Uitterlinden AG, Hofman A, Buhre PJ, Straus S, De Smet PA, and Stricker BH
- Subjects
- Aged, Aged, 80 and over, Blood Coagulation drug effects, Cohort Studies, Cyclohexanols pharmacology, Drug Interactions, Fluvoxamine pharmacology, Hemorrhage chemically induced, Humans, Middle Aged, Proportional Hazards Models, Risk Factors, Venlafaxine Hydrochloride, Acenocoumarol therapeutic use, Anticoagulants therapeutic use, Antidepressive Agents pharmacology, Serotonin pharmacology, Selective Serotonin Reuptake Inhibitors pharmacology
- Abstract
Aim: The aim of this study was to investigate the effects of co-medication with selective serotonin re-uptake inhibitors (SSRIs) on overanticoagulation during acenocoumarol maintenance treatment., Methods: All subjects from The Rotterdam Study who received acenocoumarol maintenance treatment between April 1 1991 and September 9 2009 were followed for the event of an international normalized ratio (INR) ≥6, until death, end of treatment or end of the study period. With the Andersen-Gill extension of the Cox proportional hazards model, risks for repeated events of overanticoagulation in relation to concomitant SSRI use were calculated., Results: The risk for overanticoagulation during acenocoumarol maintenance treatment was increased in combination with fluvoxamine (HR 2.63, 95% CI 1.49, 4.66) and venlafaxine (HR 2.19, 95% CI 1.21, 3.99). There was no increase in risk for the other SSRIs, but numbers of exposed cases were low for all SSRIs except paroxetine., Conclusion: Fluvoxamine and venlafaxine were associated with a more than double risk of INR values ≥6 in acenocoumarol treated subjects., (© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.)
- Published
- 2011
- Full Text
- View/download PDF
6. Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment.
- Author
-
Teichert M, van Noord C, Uitterlinden AG, Hofman A, Buhre PN, De Smet PA, Straus S, Stricker BH, and Visser LE
- Subjects
- Age Distribution, Aged, Aged, 80 and over, Aryl Hydrocarbon Hydroxylases genetics, Blood Coagulation drug effects, Blood Coagulation genetics, Blood Coagulation Disorders genetics, Cytochrome P-450 CYP2C19, Drug Synergism, Female, Genotype, Humans, International Normalized Ratio, Male, Middle Aged, Prospective Studies, Risk Assessment methods, Acenocoumarol adverse effects, Anticoagulants adverse effects, Blood Coagulation Disorders chemically induced, Proton Pump Inhibitors adverse effects
- Abstract
In the Netherlands, several reports have described a potentiation of acenocoumarol-induced anticoagulation by co-medication of omeprazole or esomeprazole and competitive inhibition of CYP2C19 has been suggested as a possible mechanism for this interaction. We conducted an observational cohort study to investigate the effects of various proton pump inhibitors (PPIs) on acenocoumarol effectiveness. All 2755 subjects from the Rotterdam Study who received acenocoumarol maintenance treatment between April 1st, 1991 and September 9th, 2009 were followed for events of an international normalized ratio (INR)≥6, until death, end of treatment, or end of the study period. The Andersen-Gill extension of the Cox proportional hazards model was used to calculate risks for repeated events of overanticoagulation in relation to concomitant PPI use. The risk for overanticoagulation was most pronounced for esomeprazole (HR 1·99, 95% CI 1·55-2·55) and lansoprazole (HR 1·49, 95% CI 1·05-2·10). There was also a lower and non-significant risk increase for the other PPIs. We did not detect a modification of these results by CYP2C19*2 genotype. Caution should be paid to co-medication with esomeprazole and lansoprazole during acenocoumarol treatment and possibly also with other PPIs., (© 2011 Blackwell Publishing Ltd.)
- Published
- 2011
- Full Text
- View/download PDF
7. A genome-wide association study of acenocoumarol maintenance dosage.
- Author
-
Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RH, Hofman A, De Smet PA, van Gelder T, Visser LE, and Stricker BH
- Subjects
- Aged, Aged, 80 and over, Aryl Hydrocarbon Hydroxylases genetics, Cytochrome P-450 CYP2C9, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Mixed Function Oxygenases genetics, Polymorphism, Single Nucleotide, Prospective Studies, Vitamin K Epoxide Reductases, Acenocoumarol administration & dosage, Anticoagulants administration & dosage, Drug Therapy, Genome-Wide Association Study
- Abstract
Several genome-wide association studies have been performed on warfarin. For acenocoumarol, the most frequently used coumarin in many countries worldwide, pharmacodynamic influences are expected to be comparable. Pharmacokinetics however might differ. We aimed to confirm known or identify new genetic variants contributing to interindividual variation on stabilized acenocoumarol dosage by a GWAS. The index population consisted of 1451 Caucasian subjects from the Rotterdam study and results were replicated in 287 subjects from the Rotterdam study extended cohort. Both cohorts were genotyped on the Illumina 550K Human Map SNP array. From polymorphisms tested for association with acenocoumarol dosage, 35 single nucleotide polymorphisms (SNPs) on chromosome 16 and 18 SNPs on chromosome 10 reached genome-wide significance. The SNP with the lowest P-value was rs10871454 on chromosome 16 linked to SNPs within the vitamin K epoxide reductase complex subunit 1 (VKORC1) (P = 2.0 x 10(-123)). The lowest P-value on chromosome 10 was obtained by rs4086116 within cytochrome P450 2C9 (CYP2C9) (P = 3.3 x 10(-24)). After adjustment for these SNPs, the rs2108622 polymorphism within cytochrome P450 4F2 (CYP4F2) gene on chromosome 19 reached genome-wide significance (P = 2.0 x 10(-8)). On chromosome 10, we further identified genetic variation in the cytochrome P450 2C18 (CYP2C18) gene contributing to variance of acenocoumarol dosage. Thus we confirmed earlier findings that acenocoumarol dosage mainly depends on polymorphisms in the VKORC1 and CYP2C9 genes. Besides age, gender, body mass index and target INR, one polymorphism within each of the VKORC1, CYP2C9, CYP4F2 and CYP2C18 genes could explain 48.8% of acenocoumarol dosage variation.
- Published
- 2009
- Full Text
- View/download PDF
8. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.
- Author
-
Teichert M, van Schaik RH, Hofman A, Uitterlinden AG, de Smet PA, Stricker BH, and Visser LE
- Subjects
- Acenocoumarol therapeutic use, Aged, Aged, 80 and over, Alleles, Anticoagulants therapeutic use, Aryl Hydrocarbon Hydroxylases antagonists & inhibitors, Cohort Studies, Cytochrome P-450 CYP2C9, Female, Genetic Variation genetics, Genotype, Humans, Male, Mixed Function Oxygenases antagonists & inhibitors, Polymorphism, Genetic genetics, Prospective Studies, Vitamin K Epoxide Reductases, Acenocoumarol pharmacology, Anticoagulants pharmacology, Aryl Hydrocarbon Hydroxylases genetics, Aryl Hydrocarbon Hydroxylases metabolism, Mixed Function Oxygenases genetics, Mixed Function Oxygenases metabolism
- Abstract
The objective of this study was to investigate the influence of genotypes associated with reduced activity of vitamin K epoxide reductase complex subunit 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) on anticoagulation with acenocoumarol during the first 6 weeks of treatment. In 1,525 patients from the Rotterdam Study who were started on anticoagulation therapy with acenocoumarol, the presence of VKORC1 1173C>T and CYP2C9*2 and *3 allele variants was determined. The first international normalized ratio (INR) after initial standard dose, risk of overanticoagulation, and mean dosage at the end of the initiation period were compared between genotypes. The initial standard dosage significantly increased the risk of severe overanticoagulation by 85% for each additional VKORC1 T-allele present. At the end of the initiation period, each VKORC1 T-allele present was shown to decrease the required acenocoumarol dosage by 5.1 mg/week, while each CYP2C9 variant allele present reduced the required dosage by 1.8 mg/week. Our conclusion was that an initial standard dosing regimen with acenocoumarol increases the risk of severe overanticoagulation in patients with variant alleles of the VKORC1 and CYP2C9 genes.
- Published
- 2009
- Full Text
- View/download PDF
9. CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?
- Author
-
Schalekamp T, Boink GJ, Visser LE, Stricker BH, de Boer A, and Klungel OH
- Subjects
- Acenocoumarol administration & dosage, Anticoagulants administration & dosage, Blood Coagulation Disorders chemically induced, Blood Coagulation Disorders epidemiology, Cost-Benefit Analysis, Cytochrome P-450 CYP2C9, Genotype, Humans, Models, Statistical, Netherlands epidemiology, Acenocoumarol adverse effects, Anticoagulants adverse effects, Aryl Hydrocarbon Hydroxylases genetics, Blood Coagulation Disorders genetics, International Normalized Ratio economics
- Published
- 2006
- Full Text
- View/download PDF
10. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
- Author
-
Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, and Stricker BH
- Subjects
- Acenocoumarol adverse effects, Aged, Aged, 80 and over, Alleles, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Anticoagulants adverse effects, Aryl Hydrocarbon Hydroxylases metabolism, Cohort Studies, Cytochrome P-450 CYP2C9, Drug Interactions genetics, Drug Interactions physiology, Drug Overdose, Female, Humans, Male, Middle Aged, Phenprocoumon adverse effects, Polymorphism, Genetic, Acenocoumarol metabolism, Anti-Inflammatory Agents, Non-Steroidal metabolism, Anticoagulants metabolism, Aryl Hydrocarbon Hydroxylases genetics, Phenprocoumon metabolism
- Abstract
Introduction: Cytochrome P450 (CYP) plays a key role in the metabolism of coumarin anticoagulants and nonsteroidal anti-inflammatory drugs (NSAIDs). Because CYP2C9 is a genetically polymorphic enzyme, genetic variability could play an important role in the potential interaction between NSAIDs and coumarins. We investigated whether NSAIDs were associated with overanticoagulation during therapy with coumarins and evaluated the effect of the CYP2C9 polymorphisms on this potential interaction., Methods: We conducted a population-based cohort study among patients of an anticoagulation clinic who were treated with acenocoumarol or phenprocoumon between April 1, 1991, and May 31, 2003, and whose CYP2C9 status was known. Patients were followed up until an international normalized ratio (INR) of 6.0 or greater was reached or until the end of treatment, death, or the end of the study. Proportional hazards regression analysis was used to estimate the risk of an INR of 6.0 or greater in relation to concomitant use of a coumarin anticoagulant and NSAIDs after adjustment for several potentially confounding factors. To study effect modification by CYP2C9 genotype, stratified analyses were performed for wild-type patients and patients with a variant genotype., Results: Of the 973 patients in the cohort, 415 had an INR of 6.0 or greater. Several NSAIDs increased the risk of overanticoagulation. The risk of overanticoagulation was 2.98 (95% confidence interval, 1.09-7.02) in coumarin-treated patients taking NSAIDs with a CYP2C9*2 allele and 10.8 (95% confidence interval, 2.57-34.6) in those with a CYP2C9*3 allele., Conclusions: Several NSAIDs were associated with overanticoagulation. For NSAIDs that are known CYP2C9 substrates, this risk was modified by allelic variants of CYP2C9. More frequent INR monitoring of patients taking NSAIDs is warranted.
- Published
- 2005
- Full Text
- View/download PDF
11. Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants.
- Author
-
Visser LE, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, and Stricker BH
- Subjects
- Acenocoumarol pharmacology, Aged, Blood Coagulation, Cohort Studies, Female, Homozygote, Humans, International Normalized Ratio, Male, Middle Aged, Phenprocoumon pharmacology, Time Factors, Vitamin K metabolism, Alleles, Anticoagulants administration & dosage, Apolipoproteins E genetics, Coumarins administration & dosage, Genotype
- Abstract
Objective: Vitamin K is an essential cofactor for the synthesis of several blood coagulation factors. It has been suggested that the apolipoprotein E (ApoE) genotype has profound effects on vitamin K status. Therefore, we investigated whether this common genetic polymorphism influenced dose requirements and effects of coumarin anticoagulants., Methods: We did a cohort study in 1637 patients from an outpatient anticoagulation clinic treated with acenocoumarol or phenprocoumon., Results: To attain the same level of anticoagulation, patients with genotype epsilon4/epsilon4 and genotype epsilon3/epsilon4 required respectively 3.4 mg (95%CI: -6.0 to -0.9) and 0.8 mg (95%CI: -1.6 to 0.1) acenocoumarol per week less than patients with genotype epsilon3/epsilon3. Patients homozygous for the epsilon2 allele required 3.5 mg (95%CI: 0.1 to 6.9) acenocoumarol per week more than patients with genotype epsilon3/epsilon3. The acenocoumarol maintenance dose showed a gene dose effect of the epsilon4 allele, but not of the epsilon2 allele. No significant dose difference was observed for phenprocoumon, possibly because of low numbers., Conclusion: The ApoE genotype affects the dose requirements of acenocoumarol.
- Published
- 2005
- Full Text
- View/download PDF
12. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants.
- Author
-
Visser LE, Bleumink GS, Trienekens PH, Vulto AG, Hofman A, and Stricker BH
- Subjects
- Acenocoumarol pharmacology, Aged, Anticoagulants pharmacology, Blood Coagulation drug effects, Drug Administration Schedule, Drug Monitoring, Female, Follow-Up Studies, Humans, International Normalized Ratio, Male, Middle Aged, Phenprocoumon pharmacology, Risk Factors, Acenocoumarol administration & dosage, Anticoagulants administration & dosage, Heart Failure blood, Phenprocoumon administration & dosage
- Abstract
Heart failure has been identified as a risk factor for increased coumarin anticoagulant responsiveness in several small-scale experiments. Epidemiological studies quantifying the risk of overanticoagulation by heart failure in a non-selected population on coumarins are scarce. Therefore, we investigated whether patients with heart failure have an increased risk of overanticoagulation and determined the effect of incidental heart failure on coumarin dose requirements. A cohort study of all patients was performed from an outpatient anticoagulation clinic treated with acenocoumarol or phenprocoumon between 1 January 1990 and 1 January 2000. All cohort members were followed until the first occurrence of an international normalized ratio (INR) > or = 6.0, the last INR assessment, death, loss to follow-up, or end of the study period. Of the 1077 patients in the cohort, 396 developed an INR > or = 6.0. The risk of overanticoagulation was 1.66 [95% confidence interval (CI): 1.33-2.07] for cases of prevalent heart failure and 1.91 (95%CI: 1.31-2.79) for incidental cases. The decrease in dose requirements in patients with incidental heart failure showed a significant trend from the fifth INR measurement preceding the date of incidental heart failure to the third measurement after this date. Heart failure is an independent risk factor for overanticoagulation. Therefore, patients with heart failure should be closely monitored to prevent potential bleeding complications., (Copyright 2004 Blackwell Publishing Ltd)
- Published
- 2004
- Full Text
- View/download PDF
13. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
- Author
-
Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, and Stricker BH
- Subjects
- Acenocoumarol metabolism, Aged, Alleles, Anticoagulants metabolism, Aryl Hydrocarbon Hydroxylases metabolism, Base Sequence, Cohort Studies, Cytochrome P-450 CYP2C9, DNA genetics, Female, Genotype, Hemorrhage enzymology, Hemorrhage genetics, Humans, Male, Middle Aged, Phenprocoumon metabolism, Risk Factors, Acenocoumarol adverse effects, Anticoagulants adverse effects, Aryl Hydrocarbon Hydroxylases genetics, Hemorrhage etiology, Phenprocoumon adverse effects
- Abstract
The principal enzyme involved in coumarin metabolism is CYP2C9. Allelic variants of CYP2C9, CYP2C9*2 and CYP2C9*3, code for enzymes with reduced activity. Despite increasing evidence that patients with these genetic variants require lower maintenance doses of anticoagulant therapy, there is lack of agreement among studies on the risk of bleeding and CYP2C9 polymorphisms. It was, therefore, our objective to study the effect of the CYP2C9 polymorphisms on bleeding complications during initiation and maintenance phases of coumarin anticoagulant therapy. The design of the study was a population-based cohort in a sample of the Rotterdam Study, a study in 7,983 subjects. All patients who started treatment with acenocoumarol or phenprocoumon in the study period from January 1, 1991 through December 31, 1998 and for whom INR data were available were included. Patients were followed until a bleeding complication, the end of their treatment, death or end of the study period. Proportional hazards regression analysis was used to estimate the risk of a bleeding complication in relation to CYP2C9 genotype after adjustment for several potentially confounding factors such as age, gender, target INR level, INR, time between INR measurements, and aspirin use. The effect of variant genotype on bleeding risk was separately examined during the initiation phase of 90 days after starting therapy with coumarins. The 996 patients with analysable data had a mean follow-up time of 481 days (1.3 years); 311 (31.2%) had at least 1 variant CYP2C9 allele and 685 (68.8%) had the wild type genotype. For patients with the wild type genotype, the rate of minor bleeding, major bleeding and fatal bleeding was 15.9, 3.4 and 0.2 per 100 treatment-years, respectively. For patients with a variant genotype, the rate of minor, major and fatal bleeding was 14.6, 5.4 and 0.5 per 100 treatment-years. Patients with a variant genotype on acenocoumarol had a significantly increased risk for a major bleeding event (HR 1.83, 95% CI: 1.01-3.32). During the initiation phase of therapy we found no effect of variant genotype on bleeding risk. In this study among outpatients of an anticoagulation clinic using acenocoumarol or phenprocoumon, having a variant allele of CYP2C9 was associated with an increased risk of major bleeding events in patients on acenocoumarol, but not in patients on phenprocoumon. Although one might consider the assessment of the CYP2C9 genotype of a patient for dose adjustment before starting treatment with acenocoumarol, a prospective randomised trial should demonstrate whether this reduces the increased risk of major bleeding events.
- Published
- 2004
- Full Text
- View/download PDF
14. Overanticoagulation associated with combined use of lactulose and acenocoumarol or phenprocoumon.
- Author
-
Visser LE, Penning-van Beest FJ, Wilson JH, Vulto AG, Kasbergen AA, De Smet PA, Hofman A, and Stricker BH
- Subjects
- Cohort Studies, Drug Interactions, Female, Humans, International Normalized Ratio, Male, Risk Factors, Acenocoumarol adverse effects, Anticoagulants adverse effects, Cathartics adverse effects, Hemorrhage chemically induced, Lactulose adverse effects, Phenprocoumon adverse effects
- Abstract
Some medical textbooks on drug interactions take note of the potential interaction between laxatives and coumarin anticoagulants, but epidemiological evidence that this interaction is of practical importance is lacking. We conducted a follow-up study in a large population-based cohort to investigate which laxatives are associated with overanticoagulation during therapy with coumarins. Of the 1124 patients in the cohort, 351 developed an International Normalized Ratio > or = 6.0. The only laxative with a moderate but significantly increased relative risk of overanticoagulation was lactulose (relative risk 3.4, 95% confidence interval 2.2, 5.3). In view of the widespread use of lactulose, especially among the elderly, awareness of this potential drug interaction is required.
- Published
- 2004
- Full Text
- View/download PDF
15. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
- Author
-
Visser LE, van Vliet M, van Schaik RH, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, van Duijn CM, and Stricker BH
- Subjects
- Aged, Base Sequence, Cohort Studies, Cytochrome P-450 CYP2C9, DNA Primers, Female, Genotype, Humans, Male, Middle Aged, Risk Assessment, Acenocoumarol administration & dosage, Anticoagulants administration & dosage, Aryl Hydrocarbon Hydroxylases genetics, Isoenzymes genetics, Phenprocoumon administration & dosage
- Abstract
Cytochrome P4502C9 (CYP2C9) is the main enzyme implicated in coumarin anticoagulant metabolism. The variant alleles CYP2C9*2 and CYP2C9*3 are associated with an increased response to warfarin. However, an effect on acenocoumarol dose requirements appears to be absent for the CYP2C9*2 allele and the consequences for the metabolism of phenprocoumon have not yet been established. We investigated CYP2C9 polymorphisms in relation to the international normalized ratio (INR) during the first 6 weeks of treatment and its effect on the maintenance dose in a cohort of 1124 patients from the Rotterdam Study who were treated with acenocoumarol or phenprocoumon. There was a statistically significant difference in first INR between patients with variant genotypes and those with the wild-type. Almost all acenocoumarol-treated patients with a variant genotype had a significantly higher mean INR and had a higher risk of an INR > or = 6.0 during the first 6 weeks of treatment. A clear genotype-dose relationship was found for acenocoumarol-treated patients. For patients on phenprocoumon, no significant differences were found between variant genotypes and the wild-type genotype. Individuals with one or more CYP2C9*2 or CYP2C9*3 allele(s) require a significantly lower dose of acenocoumarol compared to wild-type patients. Phenprocoumon appears to be a clinically useful alternative in patients carrying the CYP2C9*2 and *3 alleles.
- Published
- 2004
- Full Text
- View/download PDF
16. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.
- Author
-
Visser LE, Penning-van Bees FJ, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, and Stricker BH
- Subjects
- Acenocoumarol adverse effects, Acenocoumarol therapeutic use, Aged, Aged, 80 and over, Anti-Infective Agents therapeutic use, Anticoagulants therapeutic use, Cohort Studies, Drug Interactions, Drug Overdose, Female, Hemorrhage chemically induced, Humans, International Normalized Ratio, Male, Middle Aged, Netherlands epidemiology, Phenprocoumon adverse effects, Phenprocoumon therapeutic use, Proportional Hazards Models, Sulfamethoxazole adverse effects, Sulfamethoxazole therapeutic use, Trimethoprim adverse effects, Trimethoprim therapeutic use, Anti-Infective Agents adverse effects, Anticoagulants adverse effects
- Abstract
Background: Several case reports associated combined use of coumarins and antibacterial drugs with overanticoagulation. Despite the fact that these drugs are frequently prescribed concurrently, there is little quantitative information on the risks of such complications., Objective: To study which antibacterial drugs are associated with overanticoagulation during therapy with coumarins., Design: Population-based cohort study in a sample of the Rotterdam Study., Subjects: All patients who were treated with acenocoumarol or phenprocoumon in the study period from April 1, 1991 through December 31, 1998 and for whom INR data were available., Methods: Patients were followed until an INR >/= 6.0, the end of their treatment, death or end of the study period. Proportional hazards regression analysis was used to estimate the risk of an INR >/= 6.0 in relation to concomitant use of an oral anticoagulant and antibacterial drugs after adjustment for several potentially confounding factors such as age, gender, hepatic dysfunction, malignancies, and heart failure., Results: Of the 1,124 patients in the cohort, 351 developed an INR >/= 6.0. The incidence rate was 6.9 per 10,000 treatment days. Sulfamethoxazole combined with trimethoprim most strongly increased the risk of overanticoagulation with an adjusted relative risk of 20.1 (95% CI: 10.7-37.9). Stratification showed that the induction period of overanticoagulation varied between different antibacterial drugs., Conclusion: In this study among outpatients of an anticoagulation clinic using acenocoumarol or phenprocoumon, several antibacterial drugs strongly increased the risk of overanticoagulation. Awareness of these drug interactions and more frequent monitoring of INR values during the initial stages of antibacterial drug therapy are warranted to minimize the risk of bleeding complications.
- Published
- 2002
17. Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants.
- Author
-
Visser LE, Penning-van Beest FJ, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, and Stricker BH
- Subjects
- Acenocoumarol pharmacology, Aged, Aged, 80 and over, Confidence Intervals, Cytochrome P-450 Enzyme System metabolism, Drug Synergism, Female, Follow-Up Studies, Humans, International Normalized Ratio, Male, Middle Aged, Phenprocoumon pharmacology, Steroid Hydroxylases metabolism, Anticoagulants pharmacology, Antifungal Agents pharmacology, Aryl Hydrocarbon Hydroxylases, Blood Coagulation drug effects, Coumarins pharmacology, Steroid 16-alpha-Hydroxylase
- Abstract
Background: Several case reports have associated combined use of coumarins and antifungal agents with overanticoagulation. However, we are not aware of epidemiologic studies that quantify the risk of overanticoagulation caused by antifungal agents. We conducted a follow-up study in a large population-based cohort to investigate the antifungal agents that are associated with overanticoagulation during therapy with coumarins., Methods: All patients in the Rotterdam Study who were treated with acenocoumarol or phenprocoumon in the study period from April 1, 1991, through Dec 31, 1998, and for whom international normalized ratio data were available were followed up until an INR > or =6.0, the end of their treatment, death, or the end of the study period. Proportional hazards regression analysis was used to estimate the risk of an INR > or =6.0 in relation to concomitant use of an oral anticoagulant and antifungal agents, after adjustment for several potentially confounding factors such as age, gender, hepatic dysfunction, malignancies, and heart failure., Results: Of the 1124 patients in the cohort, 351 had an INR > or =6.0. The incidence rate was 6.9 per 10,000 treatment days. Oral miconazole most strongly increased the risk of overanticoagulation with an adjusted relative risk of 36.6 (95% confidence interval [CI], 12.4-108.0)., Conclusions: In this study among outpatients of an anticoagulant clinic who were on a regimen of coumarins, oral miconazole was especially strongly associated with overanticoagulation. Awareness of these drug interactions and more frequent monitoring of INR values during the initial stages of treatment with some antifungal drugs in patients taking coumarins may minimize the risk of bleeding complications. The concurrent use of miconazole and coumarins should be discouraged.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.